eli lilly novo nordisk

Novo Nordisk, Trump and Eli Lilly

Novo Nordisk, Lilly Shares Slip on US Drug Pricing Deal

The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government programmes, including Medicare and Medicaid, and cash payers to between $149 and $350, down from $500 to $1,000. It also grants them a three-year relief from tariffs.

· 1d · on MSN

Trump announces deals with Eli Lilly, Novo Nordisk to slash weight loss drug prices, offer some Medicare coverage

· 4h

Trump rolls out pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk. Analysts say the pact raises more questions than it answers.

· 1h

Healthcare official collapses behind Trump during weight-loss jab announcement

Donald Trump has unveiled a deal to slash the price of GLP-1 weight loss drugs by two thirds.

· 1d

Trump expands critical minerals list to copper, met coal, uranium

· 8h

Colbert Gives Verdict on Trump’s Reaction After Man Collapses in Oval Office

· 20h

Doctor discusses who could benefit from Trump's deal on weight loss drugs

Mr. Trump says drug makers Eli Lilly and Novo Nordisk agreed to lower the price of their popular GLP-1 drugs.

· 9h

Trump unveils deals to lower prices of weight-loss drugs

· 1d

Eli Lilly, Novo Nordisk Cut Weight-Loss Drug Prices in Deals With Trump Administration

FOX 11 Los Angeles

Dr. Oz jumps in as drug exec collapses during Oval Office press conference

A drug executive collapsed in the Oval Office while President Donald Trump was announcing a deal with drugmakers to reduce prices. Here's what we know.

FOX 4 News Dallas-Fort Worth

Who is Gordon Findlay? Novo Nordisk executive faints in Oval Office

A drug executive collapsed in the Oval Office while President Donald Trump was announcing a deal with drugmakers to reduce prices. Here's what we know.

4don MSN

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the weight loss drug market.